The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
There will be heavy showers on Saturday though sunshine will be enjoyed by many across the UK before a similar outlook on Sunday.
It's Prince George's fourth birthday ... but how much do you actually know about the young royal? Here's your chance to find out!
A new system will allow authorities to track private drones as research finds the heavier flying gadgets could smash plane windscreens.